AstroStem-V is under clinical development by Nature Cell and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AstroStem-V’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AstroStem-V overview
AstroStem-V is under development for the treatment of pneumonia caused by coronavirus disease 2019 (COVID-19). The drug candidate comprises of allogenic adipose tissue-derived mesenchymal stem cells.
Nature Cell overview
Nature Cell is a biotechnology company that provides food and beverages and stem cell solutions. It offers products such as fruit drink, aloe drink, coffee, energy drink, korean sauce and soft drinks. The company operates a research institute that offers services for extraction, expansion, and preservation of cells. Nature Cell’s young culture technology to increase stem cell regenerative power, small culture technology to increase intravascular administration efficiency and composition technology to increase the refrigeration shelf life of cell therapy products and cancer stem cells. It also offers blood storage services. The company carries out stem cell development in the areas of hair loss therapy, therapy for infertility and technology for Alzheimer’s. Nature Cell is headquartered in Yeongdeungpo-gu, Seoul, South Korea.
For a complete picture of AstroStem-V’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
